The Institut de la Màcula carries out a programme of clinical trials for researching new treatments for vision diseases. The Institut’s clinical trials programme offers access to the latest treatments, with no cost to the patient and with a duration between 1 and 2 years
Clinical trials are the only means of access to the new medicines that are as yet unavailable on the market. At present, there are many incurable eye diseases and research into new techniques and drugs is needed to confirm their efficacy and set out on the path to treatment and cure.
From the outset, the Institut de la Màcula has undertaken clinical trials that enable us to research new treatments or new ways of using existing ones in order to cure diseases and rescue patients from vision loss. The Institut is currently working on several clinical trials. It is recruiting patients who are affected by age-related macular degeneration (AMD), both in the dry (or atrophic) and the wet (or exudative) forms of the disease and diabetic macular oedema.
Who can take part in these clinical trials?
The access of patients to clinical trials is defined by means of exhaustive assessment of the candidate’s profile and the confirmation that a set of eligibility criteria have been met in order to participate in the study and receive treatment. The medical team will use all this information before giving its final approval
What are the benefits/risks of taking part in a trial?
Participation in a clinical trial offers patients a series of advantages: the new treatment gives them the chance to receive state-of-the-art medical care from experts. This is, for the time being, also the only means of access to new drugs which are not available to the general public
Clinical trials are performed in accordance with strict ethical and scientific principles. We at the Institut apply national and international standards and policies in protection of the rights, safety and welfare of participants.
The risks of participation in a clinical trial may derive from the route of administration of the drug on the one hand and the medication on the other. The risks of the former are well-known and generally low; those deriving from the medication are only partially known but are habitually low and restricted to the eye. In any case, the patient will be informed by the investigator of the possible adverse effects and discomfort resulting from his/her participation in the study. These may vary from one patient to another.
Do patients need to pay?
The patients chosen for clinical trials are not charged for treatment and therefore it is completely free of charge
How long will the trial last?
The duration will depend on the trial in which patients participate and the results that are observed in them. Generally, this will be between one and two years maximum.